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Abstract 
 Fragile X Syndrome (FXS) is the most common, single-gene cause of heritable Autism 
Spectrum Disorder (ASD) and intellectual disability (ID). FXS is characterized by sensory 
hypersensitivity, repetitive behaviors, anxiety, social deficits, and impaired executive function; 
behavioral impairments also found in ASD. Cortical hyperexcitability has been demonstrated in 
both FXS and ASD relative to controls, which correlates with the measures of symptom severity. 
This hyperexcitability results from impaired inhibitory GABA signaling as well as exaggerated 
excitatory glutamate signaling, and a great deal of research focused on the neurobiology of ASD 
and FXS is concerned with GABA and glutamate signaling. Despite the clear significance of 
GABA and glutamate signaling, there are also significant similarities between symptomology of 
FXS and disorders associated with dopamine (DA) signaling dysfunction such as Schizophrenia 
(SZ), Parkinson’s disease (PD), attention deficit hyperactivity disorder (ADHD), and obsessive-
compulsive disorder (OCD). Furthermore, current pharmacological interventions for FXS 
commonly include drugs that effect DA signaling in some way, indicating a need to methodically 
evaluate the role of DA signaling in FXS. 
Previous research has found that spontaneous eye blink rate (SBR) is elevated in 
adolescent males with FXS, and task-related changes in SBR correlated with symptom severity 
measures. SBR is a well-established proxy measure of DA signaling in animal models, which is 
also thought to be applicable in humans. In order to provide further evidence of a significant role 
of DA signaling in FXS pathophysiology it will be important to replicate and extend research 
focusing on a correlation between SBR and symptom measures in FXS to a much larger sample 
including a wider age range and both genders.  
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Towards this goal, data from 68 FXS subjects were evaluated to quantify blink rate, and 
correlations between blink rate dynamics, clinical assessment measures, and EEG data were 
evaluated in order to evaluate the hypothesis that DA signaling plays a major role in FXS-related 
behavioral impairments. Consistent with previous research, blink rate is significantly higher in 
FXS relative to typically developing controls. Significant correlations were found between blink 
rate and several clinical measures, but the strongest correlations were found between blink rate 
measures and clinical assessments of sensory processes. Somewhat surprisingly, these 
correlations show that higher blink rate within the FXS sample is associated with reduced 
sensory impairment, which suggests a compensatory role of DA signaling associated with 
sensory processing. Together, these data support the hypothesis that DA signaling is associated 
with some FXS behavioral impairments and suggest that elevated DA signaling may represent a 
compensatory response to cortical hyperexcitability.  
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Chapter 1: Background:                   
Fragile X Syndrome 
 Fragile X Syndrome (FXS) is an X-linked developmental disorder characterized by 
intellectual disability, sensory hypersensitivity, repetitive behaviors, social anxiety, and impaired 
executive function. FXS is the most common single-gene disorder associated with intellectual 
disability and Autism Spectrum Disorder (ASD)(Hagerman et al., 2017). FXS results from 
abnormal suppression of Fragile X Mental Retardation 1 gene (FMR1) expression due to 
expansion of the CGG triplet repeat region of the 5’ UTR of the FMR1 gene. CGG repeat 
expansion leads to enhanced methylation and subsequent epigenetic silencing of gene expression 
resulting in reduced levels of Fragile X Mental Retardation Protein (FMRP)(Ashley, Wilkinson, 
Reines, & Warren, 1993). In healthy individuals the number of CGG repeats falls between 5 and 
40 repeats, while presence of 200 or more repeats results in FXS. As an X-linked disorder, FXS 
is much more prevalent in males, and FXS-related symptoms are usually more severe in males as 
well. Several psychiatric disorders are also co-morbidities of FXS including: attention deficit 
hyperactivity disorder (ADHD), anxiety, and obsessive-compulsive disorders (OCD)(Hagerman 
et al., 2017).  
Neurodevelopmental disorders are inherently difficult to study in human populations as 
non-invasive means of evaluating CNS-related gene effects in vivo are relatively rare, expensive, 
or technically challenging. Even in vitro studies are made difficult due to the inaccessibility of 
the tissues or cell populations of interest. This drove the development of the FMR1 knockout 
mouse model of FXS, which recapitulate the core behavioral, molecular, and circuit-level 
pathologies seen in humans (Krueger, Osterweil, Chen, Tye, & Bear, 2011). This model have 
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proven to be a powerful tool in parsing the effects of FMRP downregulation on the development, 
maintenance, and baseline activity of neural circuitry associated with FXS-related behavioral 
impairments such as executive dysfunction and sensory processing impairments (Dickson et al., 
2013; Rais, Binder, Razak, & Ethell, 2018).  
The neuropathology underlying FXS-related behavioral impairments is complex and 
incompletely understood (Hagerman et al., 2017). FMRP is expressed ubiquitously throughout 
the brain across developmental time periods and adulthood. Under normal circumstance it binds 
a variety of synapse-related mRNA targets associated with synaptic plasticity, stability, and 
morphology. Considering the role of its mRNA targets and its localization near synaptic 
terminals FMRP seems to play an important regulatory role at the synapse (Ashley et al., 1993). 
While the impact of FMRP suppression in FXS has regulatory implications for hundreds of 
mRNA transcripts, a great deal of the pathophysiology of FXS can be explained by GABA-ergic 
dysfunction (Heulens, D'Hulst, Braat, Rooms, & Kooy, 2010) or elevated mGluR5 activity 
(Bear, 2005; Contractor, Klyachko, & Portera-Cailliau, 2015). Dysregulation of GABA- and 
Glutamate signaling has been studied extensively in the FXS literature, and their significance 
regarding FXS-related pathologies is not in question. For example, striking research has shown 
comprehensive phenotype correction in adult FXS mice following administration of a high-
specificity mGluR5 inhibitor (Michalon et al., 2012). However, clinical trials evaluating mGluR5 
antagonists in humans have failed demonstrating the need for further research in core aspects of 
FXS neuropathology (Berry-Kravis et al., 2016).  
Considering the specific DA-associated behavioral impairments involving executive 
function, cognitive flexibility, sensory-motor gating associated with FXS, along with direct 
evidence that auditory evoked potentials are modulated by DAergic activity (Jacob & Nienborg, 
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2018), it is not unreasonable to hypothesize that central dopaminergic dysfunction also plays a 
role in the pathophysiology of FXS.  
Test batteries have been developed or modified to measure these behavioral impairments, 
which have been shown to provide valid, reproducible scores across a wide functional range of 
the FXS population; a non-trivial task in intellectually disabled populations. One relevant 
example being the Test of Attentional Performance for Children (KiTAP) (Knox et al., 2012), 
which indexes attention/executive function in terms of response time, flexibility, reaction control 
(go/nogo), and distractibility. Research in both humans and animal models of FXS has 
demonstrated that abnormal activity of dopaminergic (DA-ergic) cell populations within the 
cortico-striatal circuit correlates with impaired executive function and behavioral flexibility 
(Dickson et al., 2013; Frankland et al., 2004; Groman et al., 2014; Grossberg & Kishnan, 2018; 
Paul, Venkitaramani, & Cox, 2013). The significance of DA signaling on behavioral 
impairments associated with FXS relative to other aspects of the disorder’s pathophysiology 
remains unclear.  
Dopaminergic Activity and Cognitive Processes 
Dopamine has several, well-established roles regarding cognition, which are primarily 
driven by activity within the striatum. Phasic, stimulus-related DA release plays a role in coding 
prediction error (Hollerman & Schultz, 1998) while tonic DA levels act to enhance signal-to-
noise ratio of neural activity by suppressing activity of neurons with low membrane potential and 
enhancing activity of neurons with high membrane potentials (Frank, 2005). Of note is the 
seemingly opposing functions of D1 and D2 receptors in the PFC. Activity within a D1-rich 
neuronal pathway within the basal ganglia codes a “go” signal to allow cognitive representations 
in the cortex to be updated, which is opposed by a D2-rich pathway that encodes a “no go” signal 
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to repress competing representations. Importantly, DA has an excitatory effect on D1-expressing 
neurons and an inhibitory effect on D2-expressing neurons (Maia and Frank, 2011). Together 
this means that DA release from striatal projections (in response to positive prediction error for 
example) will facilitate activity in the “go” pathway while suppressing activity of the “no go” 
pathway, which results in a “go” signal allowing cortical representations to be updated. 
Alternatively, reduced DA levels (such as dips in striatal DA release due to negative prediction 
error) leads to disinhibition of the D2-expressing “no go” pathway which acts to enhance the 
stability of cortical representations. Consistent with this model of DA’s action as a modulator of 
cognitive flexibility/stability is supporting research demonstrating an inverted-u-shape 
association between DA levels and performance on cognitive tasks (Cools & D'Esposito, 2011).  
DA’s modulatory influence across the cortex has wide-spread, non-linear effects on 
cortical activity, which are largely driven by DA altering the activity of inhibitory interneurons 
responsible to organizing the oscillatory activity of the cortex. A variety of studies have been 
conducted in animal models to establish an association between DA signaling dynamics and 
aspects of cognitive performance. For the purpose of this research, behavioral flexibility is a 
relevant example. Dopamine transporter (DAT) knock out in the orbitofrontalcortex (OFC) and 
dorsomedial striatum (DMS) of a transgenic mouse model lead to DA depletion, which causes 
reversal learning deficits and overall reduction in activity within those brain regions. Treatment 
with targeted DA antagonists demonstrated that DAT, outside of other DA effects, modulates 
behavioral flexibility (Cybulska-Klosowicz, Dabrowska, Niedzielec, Zakrzewska, & Rozycka, 
2017). D2, but not D1, agonism improves cognitive performance in non-human primates 
(Marino & Levy, 2019). D2Rs have been shown to play a critical role in reversal learning and 
are involved in behavioral inhibition mechanisms more broadly (Linden, James, McDaniel, & 
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Jentsch, 2018).  Activity of D2-expressing neurons within the nucleus accumbens (NAc) of 
healthy mice is involved in suppression of previously-correct behavioral strategies allowing 
transfer of behavior to new strategies (Macpherson et al., 2016). In the same study, optogenetic 
activation of D1R-expressing medium spiny neurons (D1R-MSNs) of the anterior dorsomedial 
striatum (aDMS) impaired flexibility in reversal learning tasks while suppression enhanced 
reversal. Another study using positron emission tomography (PET) measures of D2R expression 
levels in non-human primates found a correlation between D2R levels and performance on task 
evaluating reversal learning and cognitive flexibility (Groman et al., 2014).   
Research in FXS as well as its animal models has demonstrated that impaired reversal 
learning and behavioral flexibility is a characteristic phenotype associated with the disorder (Van 
der Molen et al., 2012; Ventura, Pascucci, Catania, Musumeci, & Puglisi-Allegra, 2004). 
Additionally, repetitive behaviors associated with ASD and FXS have also been shown to be 
impacted by D1- and D2R activity within the striatum (Grossberg & Kishnan, 2018). Together, 
these results suggest a specific role of DA signaling in an FXS-related behavioral impairment. 
 Despite DA’s canonical role in cognitive processes, it is also involved in modulating 
cortical activity within and between functionally defined cortical regions associated with 
sociability and sensory processing (Deliano et al., 2018; Kim et al., 2014; Radwan, Dvorak, & 
Fenton, 2016) (Kehagia, Murray, & Robbins, 2010). Considering that sensory processing 
impairments constitute another core aspect of FXS pathology, DA dysfunction may play a 
significant role in this context as well. 
  
 
6 
 
Dopaminergic Modulation of Sensory Processing 
In conjunction with other monoaminergic signaling pathways, DA has been demonstrated 
to play an important role in a variety of sensory processes (Jacob & Nienborg, 2018), but, for the 
purposes of the present study, auditory processing is particularly relevant. DA signaling has been 
found to influence neuronal activity in response to auditory stimulation with heterogenous effects 
in different brain areas associated with processing auditory signals. For example, auditory 
evoked responses in the inferior colliculus (IC) are modulated by endogenous and exogenous DA 
signaling. While the effects of DA release in the IC are heterogenous at the neuronal level,  as a 
whole, the IC showed decreased neuronal firing probability and firing rate in response to an 
auditory stimulus (Hoyt, Perkel, & Portfors, 2019). Additionally, D1- and D2-like receptors in 
cochlear afferents of healthy mice exert a protective inhibitory influence in response to high 
intensity sound stimuli or hypoxia (Valdes-Baizabal, Soto, & Vega, 2015). Other research in 
non-human primates has found that electrical stimulation of the dopaminergic ventral midbrain 
decreases spontaneous firing of auditory evoked potentials in the auditory cortex as well as 
having bidirectional effects on the power of auditory evoked potentials (Huang, Mylius, Scheich, 
& Brosch, 2016). While these studies only represent a sub-set of relevant research focusing on 
the importance of DA signaling on sensory processes, they provide evidence that, in addition to 
directly effecting the circuit-level activity of the auditory cortex, DA plays an important role in 
modulating the brain’s response to auditory stimuli more broadly. Considering this, it is not 
unreasonable to hypothesize that DA signaling dysfunction in FXS may be associated with 
measures of sensory hypersensitivity as well as EEG measures indexing E/I ratio and phase 
locking through a similar mechanism as that linking DA signaling, modulation of PFC 
oscillatory activity, and behavioral flexibility. 
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Spontaneous Blink Rate and Central Dopamine Activity 
 Relative to healthy comparison groups, differences in spontaneous eyeblink rates (SBR) 
exist in populations with Parkinson’s Disease (PD) and Schizophrenia (SZ) (Chan et al., 2010; 
Karson, 1983; Levy-Gigi et al., 2019; Waltz, 2017), diseases associated with abnormal central 
dopaminergic activity. Furthermore, the direction of the change in DA-ergic function (hyper- vs. 
hypo-) positively correlates with changes in SBR (Jongkees & Colzato, 2016; Waltz, 2017). 
Importantly, changes in SBR in these populations correlate with measures of disease symptom 
severity for behavioral impairments that overlap with some of those seen in FXS (Chan et al., 
2010; Jongkees & Colzato, 2016; Levy-Gigi et al., 2019; McCutcheon, Abi-Dargham, & Howes, 
2019). Evaluation of blink rate in animals demonstrates similar strong correlations between SBR, 
central DA activity, and behavior (Desai, Neumeyer, Bergman, & Paronis, 2007; Elsworth et al., 
1991; Groman et al., 2014; Jutkiewicz & Bergman, 2004; Kleven & Koek, 1996; Linden et al., 
2018). These studies evaluated changes in SBR in response to dopamine agonists/antagonists in 
animal models and clearly demonstrated a strong positive correlation between DA receptor 
agonism and increased SBR while DA receptor antagonists reduced SBR in a dose-dependent 
manner (Desai et al., 2007; Jutkiewicz & Bergman, 2004; Kleven & Koek, 1996). Further 
research using agonists selective for specific DA receptor types found that broad activation of the 
DA-ergic cells by simultaneous activation of all DRs did not elevate SBR, but selective agonism 
did. Dopamine Receptor 1 (D1)-specific agonists elevate SBR in mice and non-human primates, 
and pre-treatment with D1-specific antagonists abolishes the SBR increase due to D1 agonist 
treatment (Groman et al., 2014; Jutkiewicz & Bergman, 2004). Similar results were found for 
D2-specific agonism/antagonism. One interesting finding is that D1- and D2-mediated SBR 
enhancement seems to be independent of one another. Pretreatment with D2-antagonists does not 
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block D1 agonist-mediated SBR enhancement and vice versa. Additionally, co-treatment with 
D1- and D2-agonists attenuated the elevation of SBR suggesting an inhibitory interaction 
between the two receptor systems (Desai et al., 2007). Importantly, in wildtype mice, D1 
receptor activity within the prefrontal cortex (PFC) induces long-lasting enhancement of 
inhibitory post-synaptic currents (iPSCs) of GABAergic interneurons. D1-mediated iPSC 
enhancement is absent in FMR1-KO mice, but cAMP mediated iPSC enhancement is unaffected 
suggesting a specific D1-related deficit in inhibitory regulation of PFC neurons (Paul et al., 
2013). Additionally, repetitive behaviors found in FXS and ASD are impacted by the activity of 
D1- and D2Rs associated with the direct- and indirect- pathways of the basal ganglia (Grossberg 
& Kishnan, 2018).  
Taken together this research demonstrates the utility of SBR as a simple, non-invasive 
measure of central DA-ergic activity in animal models which, in conjunction with behavioral 
testing, can be used to produce testable hypotheses linking DA-ergic activity of particular brain 
regions and neuronal sub-populations to the specific aspects of complex behavioral traits known 
to be impaired in FXS animal models as well as humans.  
Spontaneous Blink Rate and Central Dopamine Activity in Humans 
In addition to a wealth of data linking cognitive behaviors to DA signaling and activity of 
specific DA receptors in animal models, similar lines of research have been carried out in 
humans as well. In healthy adults DA signaling has been shown to correlate with aspects of 
executive function including performance in tasks measuring cognitive flexibility, inhibition of 
previously learned responses, and accuracy in updating (Zhang et al., 2015). Striatal DA 
signaling dynamics have been shown to relate to working memory demands during task 
performance. (Rac-Lubashevsky, Slagter, & Kessler, 2017). A wealth of research focused on the 
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role DA signaling in cognition exists, but, for the purpose the current study, the utility of using 
measures of blink rate as an index of central DA signaling is particularly significant. For 
example, SBR can be used to predict measures of cognitive flexibility known to be modulated by 
DA signaling in healthy adults (Muller et al., 2007). Furthermore, differences in blink rate 
dynamics between tasks evaluating different dimensions of executive function have been used to 
identify the differential effects of central DA activity in regard to shifting, inhibition, and 
updating aspects of executive function (Zhang et al., 2015). 
There is a great deal of interest in using blink rate as a non-invasive, low-cost measure of 
central dopaminergic activity as a clinical tool due to the relative ease that it could be 
implemented by the medical community. Additionally, if valid, it would provide an invaluable 
research tool in the context of very young or intellectually disabled subjects that would not 
tolerate other means of evaluating central DA such as PET. Similar approaches utilizing eye 
tracking/pupillometry have been demonstrated to be viable in research focusing on individuals 
with FXS (Farzin, Scaggs, Hervey, Berry-Kravis, & Hessl, 2011). SBR has been evaluated in a 
variety of disease states as well as event-related changes in blink rate (erBR) during 
administration of psychological tests targeting specific aspects of cognition, learning & memory, 
and sensory processing(Chan et al., 2010; Rac-Lubashevsky et al., 2017; Siegle, Ichikawa, & 
Steinhauer, 2008; Slagter, Georgopoulou, & Frank, 2015; Zhang et al., 2015) with significant 
correlations found within each.  
It is important to note, despite the clear and consistent correlations between central DA 
activity and SBR in animal models, this relationship is much less clear in humans. While the 
preponderance of evidence is in favor of SBR’s utility as a proxy measure of DA activity in 
humans (Jongkees & Colzato, 2016), equivocal or negative findings from a significant portion of 
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experimentally-rigorous studies(Dang et al., 2017; Sescousse et al., 2018; van der Post, de Waal, 
de Kam, Cohen, & van Gerven, 2004) demonstrate that care must be taken when using SBR to 
index central DA activity in healthy adults. Despite its variability across the healthy adult 
population, SBR has been shown to be a highly valid proxy measure of DA activity in certain 
healthy subpopulations. For example, blink rate variations due to a variety of stimulus paradigms 
in infants are highly consistent and correlate strongly with salience and other stimulus properties 
known to be coded by DA-ergic activity within the brain (Amodeo, Jacobs-Brichford, 
McMurray, & Roitman, 2017). Furthermore, the ventral striatum has been shown to be hyper-
responsive in adolescents relative to other age groups. SBR and erBR in adolescents were 
strongly positively correlated with reward-maximization behaviors in a risky decision-making 
task, a correlation which was absent in adults (Barkley-Levenson & Galvan, 2017). Interestingly, 
correlations of SBR and DA activity are much stronger and consistent in populations with 
diseases affecting central DA function (Jongkees & Colzato, 2016). 
Blink rate is impacted by a variety of external as well as internal factors that are not 
related to dopamine with anxiety, gender, and age having the greatest impact on SBR in healthy 
populations(Jongkees & Colzato, 2016). Furthermore, SBR appears to be highly variable among 
health adults, which complicates comparative studies trying to identify disease-specific blink rate 
abnormalities relative to healthy controls. The equivocal findings seen across studies correlating 
SBR to central DA activity could be explained by the significant variability among the control 
groups used for the studies. Indeed, research aimed at identifying a broadly applicable SBR 
baseline for the human population has identified a group of individuals that blink at abnormally 
high rates even though they are nominally healthy (Doughty & Naase, 2006) suggesting that 
classification of comparison groups into low- and high-SBR groups may be an important 
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consideration for comparative studies between SBR of healthy and diseased populations. While 
the utility of SBR for evaluation of central DA activity in healthy adults has not been 
conclusively established, there is compelling evidence suggesting that SBR is related to activity 
of the D2 receptor system (Groman et al., 2014). Considering the “no go” signal associated with 
D2 activity in the striatum, elevated SBR (indexing higher DA levels) would inhibit the D2R 
pathway resulting in increased cognitive flexibility; this prediction has been experimentally 
verified (Muller et al., 2007; Tharp & Pickering, 2011).  
 While correlational and theory-driven research suggests that SBR is a valid index of 
central DA, the neural circuitry through which DA influences SBR remains unclear. Currently, 
the best candidate seems to be the spinal trigeminal complex due to its role in the spontaneous 
blink generator circuit (Kaminer, Powers, Horn, Hui, & Evinger, 2011). Importantly, activity 
within basal ganglia can modulate excitability of- and inputs to the trigeminal complex via the 
inferior colliculus and nucleus raphe magnus. One mechanistic explanation has been proposed 
that DA inhibits the trigeminal complex through its effects on the nucleus raphe magnus, which 
has the net result of increasing SBR (Kaminer et al., 2011). 
Spontaneous Blink Rate and Central Dopamine Activity in FXS 
To date, relatively little research has been devoted to identification of a possible role of 
central DA-ergic dysfunction in the pathophysiology of FXS despite growing evidence of 
significant differences in SBR between adolescent males with FXS and healthy comparisons 
(Roberts, Symons, Johnson, Hatton, & Boccia, 2005). The changes in SBR between a passive 
and cognitive task in this sample correlated with measures of FXS-related behavioral 
impairments known to involve DA-ergic signaling (Grossberg & Kishnan, 2018; Hagerman et 
al., 2017). Taken together, this body of research suggests that central DA-ergic activity may play 
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a relatively unexplored role in aspects of FXS behavioral impairment, which may be evaluated in 
a human sample using non-invasive techniques of EEG and blink rate analysis in conjunction 
with behavioral testing. 
These findings are relevant through the lens of the imbalance between excitatory and 
inhibitory signaling within the cortex that is associated with behavioral impairments seen in 
FXS. An association between SBR and D1R activity, in the context of impaired behavioral 
flexibility is interesting, but a correlation between SBR and measures of cortical 
hyperexcitability would provide a more compelling correlational link between a behavior, 
symptom measures, and underlying biology. Considering the compelling electrophysiological 
data suggesting cortical hyperexcitability, as indexed by elevated gamma power, correlates with 
measures of sensory hypersensitivity (Ethridge et al., 2019; Ethridge et al., 2016; Lovelace, 
Ethell, Binder, & Razak, 2018; Wang et al., 2017), a correlation between SBR and these types of 
EEG measures in relation to cognitive performance may be informative. Additionally, similar 
correlations with sensory processing measures would provide evidence of a relatively unexplored 
role of DA signaling in FXS. 
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Chapter 2: Overview of Experiment        
Purpose: 
 There is relatively little research exploring the role for DA-ergic dysfunction in FXS-
related pathology despite a growing body of evidence supporting this hypothesis. Existing 
research identifying correlations linking SBR and degree of behavioral impairment in FXS have 
focused on SBR differences among adolescent males with FXS and healthy controls. The 
primary goal of this research is to provide further support for the hypothesis that DA-ergic 
dysfunction is a core FXS-related pathology by extending findings of a correlation between 
symptom severity measures and SBR across a broader age range, including both genders in an 
FXS sample. The secondary goal is to identify further significant correlations between SBR, 
clinical measures, and electrophysiological recordings of brain activity as measured by EEG to 
generate data-driven hypotheses regarding the impact of DA-ergic activity on specific aspects of 
FXS-related neuropathology. These techniques are non-invasive, well-tolerated by low-
functioning/intellectually disabled populations, and translate well between animal models and 
humans, perfectly situating this approach for evaluation of central DA-ergic activity in a variety 
of difficult-to-study neurodevelopmental disorders.   
Objectives: 
The first phase of this research is to replicate previous findings of a correlation between 
FXS symptom severity and elevated SBR in adolescent males with FXS relative to healthy 
controls and extend this analysis to a larger age range across genders. Similar correlations 
between symptom severity and elevated SBR across the FXS population would further support 
the hypothesis that abnormal DA-ergic activity is a core component of FXS-related pathology. 
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The second phase of this research is to evaluate the FXS cohort based on factors known 
to affect SBR such as gender, age, co-morbidity of DA-related disorders, and treatment with 
stimulant/anti-psychotic medications to establish appropriate stratification protocols. Assuming 
significant factor effects, stratification of the FXS sample based on these factors and comparison 
of SBR correlations between sub-groups would further refine hypotheses regarding central DA-
ergic function in the context of different FXS subpopulations. Additionally, SBR variability in 
the healthy comparison group will be evaluated in order to produce an appropriate comparison 
group. A bimodal distribution of SBR across healthy controls would justify stratification of 
healthy individuals into High vs. Low SBR groups for these comparisons.  
Lastly correlations will be made between EEG data, clinical measures, and blink rate 
measures with the goal of associating DA activity, measures of symptom severity, and direct 
measurements of CNS activity. This approach would provide evidence directly linking a 
behavioral measure (ostensibly indexing DA-ergic activity), specific behavioral impairments, 
and underlying biological differences resulting in altered brain activity.  Significant differences 
among EEG data for FXS sub-groups would provide useful insight for future studies regarding 
appropriate stratification of FXS samples. This approach, which is feasible in very young or 
intellectually disabled populations, has the potential to provide a wide range of specific 
hypotheses regarding DA’s role across domains of FXS-associated behavioral deficits. These 
hypotheses can then be rigorously tested in animal models, which may provide novel therapeutic 
targets for further translational studies. 
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Chapter 3: Method           
Data Collection 
The data used in this research consists of baseline measurements taken from an ongoing 
study of FXS-related sensory hypersensitivity (Ethridge et al., 2019) in which EEG recordings 
from FXS and typically developing control (TDC) samples were made during resting and passive 
auditory habituation and frequency matching tasks. Additionally, clinical assessments were made 
using several caregiver-report surveys, as well as cognitive testing protocols (see below for 
description of EEG protocols and clinical assessments). 
Participants: 
 Baseline data from 125 subjects were included in this study, consisting of 68 individuals 
with full mutation FXS [Mean age = 21.7, standard deviation (SD) = 10.7; age range 6-53; 32 
females] and 57 age- and sex-matched typically developing controls (Mean age =26.5, SD = 
14.9; age range 6-63; 28 female). TDCs had no prior diagnosis or treatment for neuropsychiatric 
illness as reported in clinical history interviews. Exclusion criteria for the FXS sample included 
history of seizures and treatment with anticonvulsant medications or benzodiazepines due to their 
known EEG effects. Samples vary slightly across tasks due to non-compliance and data quality 
issues. Refer to Table 1 for sample characteristics.  
Procedure: 
Clinical Evaluation: The following clinical assessment measures were utilized to evaluate 
symptom severity in the FXS sample: The Child Sensory Profile (CSP; (Brown, Tollefson, 
Dunn, Cromwell, & Filion, 2001)), the Social and Communication Questionnaire (SCQ; Rutter 
et al., 2003), Anxiety Depression and Mood Scale (ADAMS, Esbensen et al. 2003), and the 
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Aberrant Behavior Checklist-Community (ABC-C;(Sansone et al., 2012)). Additionally, the 
Woodcock-Johnson III Tests of Cognitive Abilities Auditory Attention subscale (McGrew and 
Woodcock, 2001), the Vineland Adaptive Behavior Scales (Sparrow et al., 2005), and the 
computerized Test of Attentional Performance for Children (kiTAP; (Knox et al., 2012)) were 
administered. IQ was measured in both FXS and TDC using the Stanford-Binet Intelligence 
Scale 5th Ed. Abbreviated IQ (Roid, 2003), and the TDC sample completed the SCQ, ADAMS, 
ABC-C, and KiTAP. 
EEG Recording: Continuous EEG data was recorded at 1000Hz, filtered from 0.01 – 100Hz, 
referenced to Cz, and amplified 10,000X via a saline-based, 128-channel Electrical Geodesics 
system (EGI, Eugene, Oregon). Sensor placement of 128-channel EGI Hydrocel nets 
approximates the International 10/10 system (Russell, Jeffrey Eriksen, Poolman, Luu, & Tucker, 
2005). Participants were seated throughout the recording and watched a silent movie during 
testing to improve behavioral compliance. Stimuli were delivered at 65db through headphones in 
each auditory task. 
Resting EEG: Three minutes of EEG data were collected for each participant while watching a 
movie with no additional stimulation.  
Auditory Habituation Task: The stimulus associated with this task consisted of 150 stimulus 
trains composed of four 50ms bursts of white noise with a 500ms inter-stimulus interval. 
Stimulus trains were separated by 4000ms inter-trial intervals. Auditory habituation, in this 
context, refers to a reduced amplitude of subsequent stimulus-related N1 ERP components 
relative to the N1 amplitude for the initial stimulus of the train.  
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Chirp Task: The auditory chirp stimulus is characterized by a white noise carrier wave, which is 
amplitude modulated by a linearly increasing frequency from 0 to 100Hz over 2000ms. 200 chirp 
stimuli were presented over the course of the task, separated by randomly-jittered, 1500-2000ms 
inter-trial intervals. 
EEG Data Processing: Raw data were evaluated offline, bad channels were identified and 
interpolated (5% of sensors or less per subject, 2 or fewer contiguous sensors) via spherical 
spline interpolation in BESA 6.1 (MEGIS Software, Grafelfing, Germany). Data were high- and 
low-pass filtered from 0.5 to 120Hz with 12 and 24 db/octave roll-offs respectively (zero phase; 
60 Hz notch filter). Segments of data with significant movement artifacts were removed to 
improve performance of independent component analysis (ICA; Infomax) implemented in 
EEGlab 14.1.1 (Delorme & Makeig, 2004) through Matlab (The Mathworks, Natick, MA). 
Following ICA, components associated with eye-, cardiac-, and muscle-related artifacts were 
removed by researchers blind to participant group. For both auditory tasks, data was epoched 
into 3250ms trials (-500ms pre-stimulus, 2750ms post-stimulus). Data were averaged across 
trials and base-line corrected using the 500ms pre-stimulus period for ERP analyses. ERPs for 
the habituation task were low-pass filtered at 40Hz; chirp ERPs and single-trial power data were 
low-pass filtered at 120Hz. Number of retained trials for both chirp and hab was greater in the 
TDC group relative to FXS, so valid trial count was included as a covariate for all analyses. 
Resting EEG data has yet to be evaluated and will not be included in the EEG correlation 
analyses. 23 sensors across the fronto-central scalp were chosen to average across a priori for all 
subsequent analyses based on a spatial distribution of sensors consistent with previous literature 
aimed at measuring activity in the auditory cortex (Fig. 6). Single-trial power (STP) and inter-
trial coherence (ITC) measures for un-baseline-corrected, epoched, single-trial data were 
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obtained using Morlet wavelets with 1Hz frequency step utilizing a cycle length of 1 cycle at the 
lowest frequency that linearly increased to 30 cycles at the highest frequency. STP and ITC 
measure frequency-specific response amplitude and phase-locking of neural activity to the 
auditory stimuli respectively.  
Characterizing Blinks: The first three minutes of Raw EEG data from resting, habituation, and 
chirp tasks were used for identification of blinks using the Brain Electrical Source Analysis 6.1 
(BESA) software package. EEG data was filtered to 0.5 (12dB/octave slope; zero phase) to 50Hz 
(24 dB/octave slope; zero-phase) with a 60Hz notch filter. Virtual electrooculograms for 
horizontal and vertical eye movement components were plotted alongside channel data. Blinks 
were identified by comparison of EEG and vEOG waveforms, alongside topographical analysis 
of electrical activity on the scalp (Figure 5.) and blinks were marked at their peak amplitude for 
downstream analyses of stimulus-related effects on blink rate.  
Blink Counts: Total blink counts for each subject were independently coded by two trained 
researchers, and Inter-rater reliability was calculated as the total percentage of subjects with at 
least 90% agreement between raters (IRR = 92%). No subjects had <80% agreement among 
blink counts, which was the threshold for omission from further analysis.  
Blink Measures: Matlab R2017a (The Mathworks, Natick, MA) was used to calculate 
spontaneous blink rate (SBR), event-related blink rate (erBR), blink latency following stimulus 
onset, and blink variability (StDev). Event-related blinks refer to any blinks that occur within 
500ms epochs following stimulus offset. Event-related eyeblink rate (erBR) was calculated by 
dividing the total number of event-related blinks by the summation of all stimulus-related 
epochs. Stimulus-related blink latencies for each subject were calculated by averaging the 
latencies between stimulus onset and the first event-related blink across trials. Spontaneous blink 
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rate (SBR) was calculated as the difference between total blink count and event-related blink 
counts divided by the difference of total time and summed stimulus-related epoch duration. 
Lastly, data was segmented into 3 second bins, and the standard deviation was calculated based 
on the number of blinks in each bin to provide a measure of blink variability for each subject. 
EEG Results 
Refer to (Ethridge et al., 2019) for a full account of the results of the EEG analysis described 
above. The EEG measures utilized in the research discussed here will be briefly outlined below. 
Habituation Task EEG Results 
N1: The initial N1 component of the ERP associated with the habituation task had a significantly 
higher amplitude in FXS compared to control; however, habituation of N1 amplitude for 
subsequent repetitions within stimulus trains was not different between FXS and TDC samples 
(percent change in amplitude between initial and subsequent N1s was not different between 
groups). There were also no significant differences between groups regarding N1 latency 
following stimulus onset. 
P2: Similar to N1, initial P2 ERP components had significantly higher amplitude in the FXS 
sample, which was significantly reduced across stimulus repetitions indicating habituation had 
occurred. The percent change in P2 amplitude was not different between FXS and TDC. 
However, P2 latency was significantly shorter in FXS relative to controls. 
Single Trial Power: Analysis of time frequency plots of STP identified 3 time-frequency 
clusters that differ significantly between FXS and TDC samples. Theta band (3-7Hz) power was 
significantly higher in the FXS sample (no significant effects of trial number or sex). Alpha (8-
12Hz) power was not significantly different between groups. However, there was a significant 
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group*sex interaction with females with FXS showing higher alpha power than TDC females. A 
marginal effect of group on gamma (31-70Hz) power was found, suggesting higher gamma 
power in FXS. 
Chirp Task EEG Results 
Single Trial Power: Analysis of time frequency plots of ITC and STP identified 4 time-
frequency clusters significantly different between FXS and TDC. FXS showed significantly 
stronger alpha band phase-locking (ITC) to stimulus onset relative to controls. A significant main 
effect of group was found for ITC to the chirp stimulus while it was in the low gamma 
oscillatory range (31-57Hz) suggesting that the TDC sample was better able to modulate neural 
oscillations in the low-gamma band to match those of the stimulus. Furthermore, a group*sex 
interaction indicated FXS females were more like male and female controls than FXS males. 
Gender and group effects were found for theta (3-7Hz) power, which indicated higher theta 
power in FXS. Females with FXS showed higher theta power than TDC females, but theta power 
for males did not differ between groups. A main effect of group on gamma power (31-70Hz) was 
found suggesting higher gamma power in FXS than TDCs. 
Gamma power and Phase-locking: Elevated single trial power in the gamma band significantly 
correlated with decreased phase-locking to the chirp stimulus in the gamma frequency range in 
the TDC sample. A similar effect was found in FXS, but the correlation was not significant 
Analysis 
Blink Rate Analysis: All statistical tests were carried out using SPSS version 25. Differences 
between SBR, erBR, blink latency, and blink variability for FXS and control samples were 
evaluated by ANOVAs with factors of group and sex, including age as a covariate. Task effects 
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were evaluated using mixed-effects ANOVAs with within-subjects factor of task and between-
subjects factors of group, and sex, with age as a covariate. Similarly, stimulus effects were 
evaluated for each task using mixed-effects ANOVAs with within-subject factor of stimulus 
(spontaneous vs. event-related blink rate) and between-subjects factors of group and sex, 
including age as a covariate. 
 Clinical Correlations: Blink measures found to be significantly different between FXS and 
control groups were then correlated with clinical and EEG measures. Spearman’s correlations 
were calculated, and significant correlations between blink measures and clinical or EEG 
measures were identified within the FXS group. The Benjamini-Hochberg procedure was used to 
correct for false discover rate due to the large number of comparisons. Additionally, correlations 
will be separated by gender due to the interaction between gender and cognitive ability in FXS 
Significant correlations can be found in Appendix B (Tables 4-8). 
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Chapter 4: Results           
Group Differences in Blink Rate Measures 
Blink Rate Distributions: Evaluation of resting SBR distribution between FXS and TDC groups 
did not demonstrate any significant differences. SBR did not appear to be bimodally distributed 
in the TDC group so the entire sample was included in further analyses (Figure 1 & 1a). 
Rest: Mean spontaneous blink rate was 0.321 blinks/sec (.21) in the FXS sample, which was 
significantly higher than mean SBR of 0.234 blinks/sec (.15) in controls (F1,115 = 6.332, p = 
0.013). No significant effects were found for sex (F1,115 = .062, p =.804) or age (F1,115 = 0.227, p 
= .635). Blink variability (StDev) did not vary significantly between groups (F1,115 = 2.646, p = 
.107), sexes (F1,115 = 0.000, p = .997), or ages (F1,115 = 0.111, p = .739).  
Chirp: A significant effect of group on blink variability (StDev) was found for the auditory 
chirp task (F1,104  = 9.163, p = 0.003) with significantly higher blink variability in the FXS group 
(Mean StDev = 0.860; (.29)) relative to TDC (Mean StDev = 0.710; (.19)). Additionally, a 
significant effect of group on SBR was found (F1,104  = 3.842, p = 0.042) with significantly 
higher SBR in the FXS group (0.33 blinks/sec) (.19) relative to controls (0.25 blinks/sec) (.18). A 
marginally significant effect of group on erBR (F1,104 = 3.842, p = 0.053) was found in the same 
direction (higher erBR in FXS). No significant effects for sex or the group*sex interaction were 
found for either erBR or SBR. 
Hab: A significant effect of group on blink variability (StDev) was observed (F1,104 = 10.032, p 
= 0.002) with significantly higher blink variability in the FXS group (Mean StDev = 0.883; 
(.28)) relative to TDC (Mean StDev = 0.730; (.19)). A significant effect of group on erBR was 
found (F1,104 = 6.581, p = 0.012) with the FXS sample exhibiting significantly greater event-
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related blink rate (0.330 blinks/sec; (.19)) relative to controls (0.240 blinks/sec; (.17)). A 
marginally significant effect of group on SBR was found (F1,104 = 3.664, p = .058) in the same 
direction (higher SBR in FXS). No significant effects of sex or sex*group were observed. 
Stimulus Effects on Blink Rate 
Chirp: Significant effects were found for stimulus (F1,104  = 3.930, p = 0.050) and the 
stimulus*sex*group interaction  (F1,104 = 5.487, p = 0.021). Aside from a significant between-
subject effect of group (F1,104 = 4.161, p = 0.044), no significant between-subject effects were 
found. Within subjects, erBR was lower relative to SBR (0.26 and 0.29 blinks/sec respectively). 
The difference between SBR and erBR is more pronounced in females relative to males (0.042 
blinks/sec increase in females relative to 0.024 blinks/sec increase in males). Viewed as a percent 
change between erBR and SBR, females show a 15.9% increase in BR while males show a 9.5% 
increase. Considering the significant stimulus*sex*group interaction, FXS and TDC females 
both showed elevated SBR relative to erBR (FXS change = 19.5%, TDC change = 11.1%), as 
did TDC males (16.7%). However, FXS males had highly similar erBR and SBR (4.1% change). 
Refer to appendix C for blink rate comparisons across tasks. 
Hab: No significant within-subject effects were found among data in the hab task. A marginally 
significant within-subject stimulus*sex interaction (F1,104 = 3.592, p = 0.061) was found, but no 
significant stimulus*group*sex interaction (F1,104 = 0.088, p = 0.768). Despite the stimulus*sex 
interaction only being marginally significant (p = 0.061) , similar to results seen in the chirp task, 
erBR and SBR were similar in males (0.285 and 0.288 blinks/sec), but erBR was lower than SBR 
in females (0.281 and 0.308 blinks/sec). A significant between-subject effect of group (F1,104 = 
5.105, p = 0.026) was found, but no significant effects of sex (F1,104 = 0.050, p = 0.823) or 
group*sex interaction (F1,104 = .527, p = 0.470).  
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Medication Effects on Blink Rate 
No significant effect of DA medication on BR in FXS was found (F1,52 = 0.018, p = 
0.894). However, there was a marginally significant effect of the sex*medication interaction on 
BR (F1,52 = 4.004, p = 0.051). Unmedicated females with FXS had higher BRs relative to 
medicated females (0.342 and 0.242 blinks/sec respectively). The opposite was true for the male 
FXS sample with unmedicated males having lower BRs relative to medicated males (0.264 and 
0.378 blinks/sec respectively). There were an insufficient number of TDC subjects taking DA 
medications to allow for comparison of medication effects across groups. 
Exploratory Clinical Correlations 
Significant correlations surviving correction for multiple comparisons are listed below. 
Refer to appendix B for a full list of significant spearman’s correlations broken down by gender 
and task (p* < 0.05, p** < 0.01). 
IQ Correlations: FXS male SBR during the chirp task correlates with deviation IQ (-.508**) 
and verbal Z-score (-.548**). Blink variability in FXS males during chirp also correlates with IQ 
(-.493**) and verbal z-score (-.591**). No significant correlations for IQ measures were found 
for BR measures in the overall FXS sample, FXS females, or TDCs (Tables 4, 4a, 4b). 
Sensory Profile Correlations: SBR during the resting task for the overall FXS sample 
correlates with CSP registration (-.652**). FXS male resting SBR also correlates with CSP 
registration (-.740**), but there is not a significant correlation between CSP scales and BR 
measures from FXS females or TDCs (Tables 4, 4a, 4b). 
Vineland Correlations: FXS male resting SBR correlates with vineland composite scores (-
.515**). FXS male blink variability during the rest task also correlates with Vineland composite- 
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(-.505**), communication- (-.505**), and daily living - (-.473**) scores. FXS male erBR during 
the habituation task correlates with Vineland coping- (.502**), communication- (-.531**), and 
composite- (-.501**) scores. Blink variability of FXS males during the habituation task also 
correlates with Vineland composite scores (-.504**). No significant correlations for BR 
measures and Vineland scores were found in FXS female and TDC samples (Tables 5, 5a, 5b). 
Cognitive Flexibility Correlations: Resting SBR in FXS males correlates with number of errors 
during a distractor task on the kiTAP (.501**). Errors during a go-no-go task correlate with SBR 
(.583**) and erBR (.596**) during habituation in FXS males. Similarly, number of errors during 
the distractor task of the kiTAP correlates with erBR (.543**) in FXS males during habituation. 
No significant correlations were found for kiTAP performance and BR measures for FXS female 
and TDC samples (Tables 7, 7a, 7b). 
EEG Correlations: Relative to the FXS sample, many significant correlations for EEG and 
blink measures can be found in the TDC sample during rest and habituation tasks (Table 8c). 
Blink variability in FXS males during habituation correlates with EEG measures of Alpha 
(.618**) and Theta (.707**) power measured during the same task. FXS female SBR during the 
rest task correlates with ERP onset ITC during the habituation task (0.845**) (Tables 8, 8a, 8b, 
8c). 
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Chapter 5: Discussion                
 This study succeeded in its primary goal in that it replicated previous findings of 
significantly elevated spontaneous blink rate in an FXS sample relative to typically developing 
controls. Importantly, this study demonstrated that this difference was true for a relatively large 
FXS sample including both genders, which suggests elevated SBR is a behavioral trait that 
manifests across the FXS population. It is worth mentioning that the primary factors known to 
impact blink rate in healthy adults (age and gender) did not significantly impact blink rate 
measures in the overall FXS sample according to the analyses conducted in this study. Gender 
effects only became apparent upon deeper investigation of blink rate dynamics between tasks 
and stimulus conditions. Generally, FXS females appeared more similar to TDCs, which mirrors 
results from behavioral and biological research into gender differences in FXS symptom 
presentation.  
 The results of our exploratory correlations between blink rate, clinical measures, and 
EEG data are somewhat surprising. The most well-established correlations between specific 
behaviors, DA signaling, and SBR are focused on cognitive measures. In the context of FXS, 
which exhibits reduced D1R expression in the PFC, elevated SBR, and impaired reversal 
learning, a theoretically sound hypothesis could be proposed linking differences in SBR to 
impairments in performance on tests of cognitive flexibility. Data exists demonstrating such a 
correlation in animal studies, but no significant correlation between blink rate measures and 
cognitive flexibility scores survived correction for multiple comparisons in the overall FXS 
sample. Despite a lack of correlation across the entire FXS sample, blink rate measures in FXS 
males significantly correlate with number of errors in distractor and go-no-go tasks on the 
kiTAP. These correlations were not seen in the FXS female sample suggesting that DA-mediated 
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cognitive flexibility is impaired in males, but not females, with FXS. It should be noted that BR 
measures taken during the chirp task did not significantly correlation with kiTAP performance, 
which indicates that, in the context of auditory processing, the habituation task may be better 
situated to evoke DA-signaling that is reflected in BR changes. Another consideration is the fact 
that the association between BR measures and clinical measures of cognitive function in FXS 
reported by (Roberts et al., 2005) were apparent only when comparing BR during a cognitive 
task and at rest. Similarly, D1R-mediated BR effects in mice were only apparent during 
cognitively demanding tasks (Dickson et al., 2013). Since all EEG tasks in this study were 
passive, that could account for the relative lack of correlations between blink rate and clinical 
measures of cognitive function.  
 The most consistent, significant correlations identified in this study for the entire FXS 
sample were between blink rate and clinical measures of sensory processing. Specifically, higher 
resting SBR leads to reduced sensory registration, avoidance, and sensitivity. While research has 
demonstrated that central DA activity can modulate auditory evoked responses in the auditory 
cortex (Huang et al., 2016), there is less known about the receptor-level interactions relative to 
the well-established D1R vs. D2R dynamics within the PFC and striatum associated with 
cognitive flexibility. Of particular interest is the fact that higher blink rate in the FXS sample 
correlate with reduced sensitivity in sensory processing scores. This contrasts our initial 
hypothesis that elevated SBR reflects exaggerated DA signaling, which would correlate with 
greater impairment in behavioral measures. Indeed, the correlations between SBR and sensory 
measures suggest a compensatory role of elevated DA signaling in the context of sensory 
processing. Similar BR dynamics between sexes in the FXS sample suggest that this correlation 
is not simply due to the fact that female BR is greater on average relative to males.  
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 A growing body of evidence exists supporting the hypothesis that the cortical 
hyperexcitability associated with FXS and ASD underlies sensory hypersensitivities 
characteristic of these disorders (Cea-Del Rio & Huntsman, 2014; Lee, Lee, & Kim, 2017; 
Nelson & Valakh, 2015). At the local circuit level, gamma band (31-70Hz) oscillatory activity is 
primarily driven by activity of inhibitory, GABA-ergic interneurons on pyramidal neurons of the 
cortex (Gibson, Bartley, Hays, & Huber, 2008). Given the well-established deficits in GABA-
ergic signaling and exaggerated glutamatergic signaling in FXS and ASD, gamma band spectral 
power as measured by EEG provides a non-invasive means of characterizing cortical 
hyperexcitability (Ethridge et al., 2016). Converging evidence from electrophysiological studies 
of auditory hypersensitivity in both humans and animal models of FXS along with cellular and 
molecular data suggest that gamma power is significantly elevated in FXS relative to healthy 
controls and that gamma power correlates with worse scores on measures of sensory processing 
and sensitivity (Ethridge et al., 2019; Goswami, Cavalier, Sridhar, Huber, & Gibson, 2019; 
Lovelace et al., 2018). With this in mind along with the modulatory effect DA signaling has on 
auditory evoked responses, a possible explanation of the seemingly compensatory effect of 
exaggerated DA signaling could be that DA acts to modulate the circuit level activity of the 
auditory cortex to reduce resting gamma power with the result of improving signal to noise ratio 
for auditory signals, which could account for reduced sensory processing impairments. This, 
however, does not seem to be the case as no significant correlation was found between blink rate 
measures and EEG measures of gamma power within the FXS sample.  
Another possible explanation of the beneficial effects of elevated DA levels focuses on 
research in mice showing that treatment with DA receptor agonists/antagonists modulates the 
phase-locking of auditory evoked potentials in the auditory cortex to stimulus characteristics 
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(Huang et al., 2016). Inter-trial coherence measures index phase-locking of neural activity to the 
stimulus and is thought to represent the ability of the cortex to reorganize its ongoing activity in 
response to a stimulus. ITC measures have been shown to be reduced in FXS and ASD samples 
relative to healthy controls, and this reduction correlates with sensory processing impairments 
(Ethridge et al., 2016; Lovelace et al., 2018; Wang et al., 2017). Elevated DA signaling could 
improve phase-locking of auditory responses to the stimulus (as indexed by greater ITC) 
resulting in reduced sensory processing impairments. Again, the correlational data from this 
study does not support this hypothesis as no significant correlations were found between blink 
rate and EEG measures of ITC for either auditory task. 
  Analyses of stimulus effects (blink rate during trials relative to between trials) 
demonstrated a clear lack of stimulus effect in the habituation task (p = 0.179) as compared to 
the significant effect found for the chirp task (p = 0.050), which suggests that the chirp stimulus 
may be better able to elicit DA effects reflected in BR differences relative to the habituation task. 
However, this interpretation is complicated by the fact that the majority of significant 
correlations for clinical and EEG measures are associated with BR measures in the habituation 
and resting tasks.  In order to interpret these results, it is important to understand the different 
neural processes driven by the two stimuli, which were engineered to elicit distinct reactions 
from the auditory cortex: habituation (reduced ERP amplitude indicating inhibition of the 
auditory response) and frequency following (reorganizing the phase of ongoing neural activity to 
synchronize with stimulus frequency). The chirp stimulus was designed to drive gamma-related 
neural oscillations while the habituation stimulus was not. The lack of correlation between BR 
during chirp, clinical measures, and gamma power in any task suggests that DA signaling 
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abnormalities in FXS are not related to re-organizing ongoing neural oscillations in the gamma 
band. 
The lack of significant correlations between blink rate and EEG measures for either task 
in the overall FXS sample is contrasted by the strong correlation between BR and EEG measures 
for the habituation task in the TDC sample. Significant correlations between BR measures and 
ERP ITC, N1 latency, and percent habituation were apparent for the TDC sample. Interestingly, 
there were no such correlations between BR and EEG measures taken during the chirp task. 
These results demonstrate that the habituation task is more suited to engage aspects of DA 
signaling that impact BR, which correlate with relevant EEG measures associated with auditory 
processes. 
 While this correlation between the BR difference and task-specific EEG measures 
support the hypothesis that DA signaling (as indexed by BR)  is actively modulating the 
responses within the auditory cortex in TDCs, the lack of a similar correlation in the FXS sample 
does not stand as evidence against that hypothesis. Considering the differential dynamics of DA-
mediated modulation of circuit-level activity associated with different neural processes, it could 
be the case that significant DA-mediated effects are occurring in parts of the auditory pathway 
outside of the auditory cortex itself. If there is some stimulus effect on DA signaling that acts 
upon upstream aspects of auditory processing, a correlation between blink rate differences and 
differences in neural activity within the auditory cortex may not be immediately apparent.  
An interesting result that came out of these analyses was the fact that males showed very 
little difference between SBR and erBR (0.285 and 0.288 blinks/sec) in the habituation task. BR 
dynamics were similar for FXS females and TDCs (decreased erBR relative to SBR), but FXS 
male SBR and erBR scores were virtually identical (0.293 and 0.305 blinks/sec).This difference 
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between FXS males and other groups was not sufficient to produce a significant 
group*sex*stimulus interaction in the habituation task (p = 0.768). However, there was a 
significant effect for the group*sex*stimulus interaction in the chirp task (p = 0.021) with FXS 
males showing no difference between erBR and SBR while FXS females and TDC males and 
females had reduced erBR relative to SBR. This dynamic of greater similarity between FXS 
females and TDCs of both genders mirrors results from EEG data in the chirp task indicating that 
FXS females’ ITC between neural activity and the chirp stimulus in the low gamma band (31-
57Hz) was more like TDCs while FXS males were significantly different. While this similarity is 
evocative, attempts to associate DA signaling to sensory processing measures via BR dynamics 
is frustrated by the lack of correlation between BR and EEG measures in the FXS sample. 
Despite this, these results stand as a potential justification for the use of BR measures as a 
hypothesis generating tool in the context of FXS.   
In addition to supporting the hypothesis that significant differences exist between DA 
signaling between FXS and healthy populations, utilizing this approach identified a possible 
compensatory relationship between elevated DA signaling and sensory processing impairments 
in FXS, which, to the author’s knowledge, represents a novel finding related to FXS 
neuropathology. Considering the inhibitory influence DA play at the circuit level in both 
cognitive and sensory processes, along with the correlation between hyperexcitability of auditory 
circuitry and sensory hypersensitivity in FXS, DA may be acting to dampen circuit activity 
resulting in reduced sensory processing impairment. Further research evaluating the role of DA 
modulation of phase-locking, habituation, and ITC in relation to sensory hypersensitivity in FXS 
samples would be informative.  
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This study was unable to achieve its tertiary goal of detecting correlations linking blink 
rate, clinical measures, and EEG data representing underlying biological activity within the FXS 
sample, which would provide a compelling hypothetical link between DA activity and sensory 
hypersensitivity with specific predictions about DA’s impact on network level activity. However, 
a biomarker’s utility is, to an extent, independent of a mechanist understanding of how it relates 
to disease pathology. If nothing else, this study demonstrates the utility of BR analyses as a tool 
for hypothesis generation and opens new avenues of research aimed at reproducing and 
validating BR as a biomarker of sensory hypersensitivity in FXS. Furthermore, the differential 
effects of the chirp and habituation stimuli on blink rates of FXS males relative to other subjects 
is exactly the kind of data necessary to identify appropriate stratification protocols for FXS 
samples, as well as informing decisions about task and stimulus characteristics for future 
research involving BR and auditory processing measures. Lastly, comparison of the remarkably 
strong correlations for BR and EEG measures during the habituation task for TDC and the lack 
of significant correlations for the same measures in the FXS group is intriguing. Assuming BR 
indexes central DA, these results suggest that DA signaling is involved in key aspects of auditory 
habituation in TDCs. The fact that these correlations are largely absent in the FXS population 
may suggest DA-mediated modulation of the auditory cortex is impaired or dysregulated in FXS. 
Why this would correlate with reduced sensory hypersensitivity is not immediately clear. 
Another important point is that, while the most consistently significant correlations 
indicated a negative relationship between blink rate and measures of sensory impairment in the 
overall FXS sample, significant correlations were found between multiple measures of adaptive 
behaviors including social, language, coping, personal skills in FXS males. While elevated BR in 
FXS males correlated with worse scores on scales measuring communication, a significant 
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positive correlation between coping skills and BR was found, suggesting that elevated DA 
signaling in FXS has complex, bi-directional effects in multiple domains including social 
behaviors as well as cognitive and sensory processes. Given the relative weakness of the 
correlation of BR and social behaviors, the known importance of task on DA signaling (as 
measured by BR), and the fact that the tasks utilized in this study focused on sensory processes, 
making any specific claims about an association between blink rate measures and DA-mediated 
social impairments would be premature. A further investigation of blink rate dynamics utilizing 
tasks focusing on social cognition, attention, and motivation in conjunction with EEG measures 
would be insightful, especially considering the significant role that DA signaling plays in 
modulating neural circuitry associated with these processes. 
An important note worth mentioning here, is that EEG data represents the cumulative 
activity of neuronal activity across levels of cortical network organization. Within a dataset a 
virtually infinite number of analytical techniques can be applied to identify signals associated 
with different levels of network organization embedded within the overall EEG signal. The lack 
of correlation between blink rate and the EEG measures used in this study may simply reflect a 
lack of resolution or specificity for the analytic approach used here to measure DA-related 
influences on network activity. Another approach to analysis of EEG data focuses on 
metastability of network activity in which changes in the complexity of the EEG signal reflect 
dynamic changes in the degree of organization of network activity. Signals with greater 
complexity (higher entropy) reflect less-organized, stochastic activity inherent in neural systems, 
while reduced signal complexity (lower entropy) reflects synchronization and organization of 
network activity. Detectable difference in entropy measures obtained using EEG have been 
found within subjects that are associated with a variety of factors including arousal, engagement, 
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task performance, as well as correlations between entropy measures and behavioral measures of 
cognitive flexibility (Frohlich, Irimia, & Jeste, 2015). Importantly, detectable differences in 
resting state set-shifting between states of high- and low- entropy can differentiate healthy from 
atypical populations such as ASD or PD (Cruz, Mallet, Magill, Brown, & Averbeck, 2009), as 
well as being able to predict an ASD diagnosis later in life with a high degree of accuracy in a 
sample of infants at high risk of developing ASD (Bosl, Tierney, Tager-Flusberg, & Nelson, 
2011). The fact that entropy measures are sensitive to task effects, differ significantly between 
healthy and atypical samples, correlate with behavioral and psychological measurements, and 
can be used to reliably predict future diagnoses make this analytic approach particularly relevant 
in the context of research focusing on identifying a correlation between blink rate and EEG 
measures (Jeste, Frohlich, & Loo, 2015). Considering the important role DA plays in modulating 
excitatory and inhibitory signals thought to underlie changes in network activity, it is not 
unreasonable to expect that DA-related changes in EEG signals may be more apparent using 
measures of entropy and metastability. Furthermore, novel analytic approaches such as this can 
be applied to existing data, which is particularly relevant for research focusing on 
neurodevelopmental disorders or other atypical populations where recruitment of subjects can be 
a significant hurdle. Given the relative dearth of studies of FXS with large sample sizes, applying 
novel analytic techniques to existing EEG datasets from such studies is a well-reasoned approach 
that can identify novel differences in neural activity across levels of biological organization of 
the brain in a cost-effective, time-efficient manner, which, in conjunction with blink rate 
analyses, has a great deal of potential for disentangling the complex, non-linear relationship 
between DA signaling, cortical network dynamics, and behavior. 
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Summary 
This study provides evidence that spontaneous blink rate is elevated in the FXS 
population relative to typically developing controls. This was true for a relatively large sample 
including both genders across a wide age range, suggesting that increased SBR is a behavioral 
difference that can be generalized to FXS as a whole. This is significant given the correlation 
between SBR differences and symptom severity in a number of disorders known to involve DA 
signaling impairments, the association between DA signaling and behavioral impairments in 
FXS and the prevalence of DAergic drug prescription to the FXS population. Further evaluating 
the hypothesis that elevated SBR in FXS represents a core deficit in DA signaling, correlations 
between SBR and clinical measure were calculated, and a negative relationship between SBR 
and symptom severity was observed for several measures of sensory processing, social 
impairments, and affect. This surprising result of a seemingly compensatory role of DA signaling 
in FXS is suggestive and demonstrates the utility of SBR analysis as a hypothesis generating 
tool. 
The finding of differential task and stimulus effects on BR based on gender and group is 
interesting, and, even without a complete mechanistic explanation for these findings, these 
results are valuable for future studies involving BR comparison among FXS and TDC groups in 
terms of stratification protocols and task/stimulus selection to maximize the likelihood of 
detecting a difference between groups. 
While no significant correlations between available EEG measures and FXS BR were 
identified, novel analytic approaches to EEG data analysis have the potential to parse DA 
signaling with a higher degree of resolution. Given the important modulatory influence DA 
exerts on circuit level activity in a variety of contexts across the cortex. The expectation of a 
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correlation between BR and EEG measure of cortical activity is not unreasonable. Indeed, EEG 
studies using measures of signal variability, metastability, and entropy have successfully 
measured changes in organization of cortical activity due to the action of DA (Cruz et al., 2009; 
Darbin et al., 2016; Shafiei et al., 2019), and, as such, a promising future line of work regarding 
the research discuss here would employ similar techniques evaluating metastability of EEG 
signals. 
The results of this study support the hypothesis that differences exist between DA 
signaling in FXS and healthy populations, and that this increase in DA signaling represents a 
compensatory response to sensory processing impairments in FXS. Valuable information 
regarding task, sex, and group differences in BR dynamics will inform future research focusing 
on these topics. Taken together, these results demonstrate the utility of the SBR analysis as a 
hypothesis generating tool and suggest that BR may be a useful monitoring biomarker for studies 
focusing on improving sensory hypersensitivity in FXS.  
Limitations and Concerns 
A number of important considerations should be discussed regarding the interpretation of 
the data presented here. First, the Child Sensory Profile was the source of clinical measures of 
sensory processing impairment, but, of the total FXS sample of 68, CSP data only exists for 28 
subjects. Evaluation of sample characteristics of those 28 subjects reveals no significant 
difference in age range relative to the entire FXS sample, however, IQ and non-verbal Z-scores 
were significantly different. Additionally, only 8 of the 28 individuals were female. With this in 
mind, care should be taken when proposing sample-wide, sensory processing effects based on a 
relatively restricted sub-set of the total sample. 
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Another significant concern regards the accuracy of coding BR manually. There is very 
little difficulty in identifying blinks in the TDC sample due to higher levels of behavioral 
compliance relative to the FXS sample. Muscle- and eye- movement related artifacts are 
significantly more prevalent in the FXS data. Clear, unambiguous blinks are common in EEG 
data from TDCs, but, within the FXS group, identification of blinks is complicated by the 
presence of significantly more artifact along with a much greater co-occurrence of blinks and 
lateral eye movements that can greatly increase the difficulty of coding blinks in the FXS sample 
relative to controls. While measures of inter-rater reliability help address this concern, percent 
agreement, the most common measure of IRR in blink rate literature, is not the most powerful 
measure of IRR. Given the high degree of agreement between raters in this study, issues 
associated with blink identification stemming from artifacts in the EEG data seem to be 
surmountable. However, evaluating IRR using higher resolution approaches would increase 
confidence in blink rate measures for FXS and help to limit introduction of further sources of 
variability. 
The fact that DA medications are commonly prescribed to FXS patients is also a relevant 
issue. Of the total FXS sample evaluated in this study, 17 were being treated with DA agonists, 
antagonists, or both simultaneously. Despite the fact that analyses demonstrated no significant 
medication effects within that sample, the number of individuals receiving any one medication 
type was insufficient to examine specific medication effects. Separating medication effects from 
underlying pathology necessitating the use of those medications is inherently difficult, 
particularly so in samples of limited size.  
The most important concern regarding this research is the validity of blink rate measures 
as an index of DA signaling. While SBR has extensive support in animal literature as a measure 
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of DA signaling, and SBR is known to be affected in human diseases involving DA dysfunction, 
across the healthy adult population a clear correlation between DA signaling and SBR has not 
been conclusively demonstrated. Indeed, even in animal models with the most robust findings of 
DA directly modulating blink rate, equivocal and null findings are not uncommon. Furthermore, 
at least three distinct types of blinking exist: Spontaneous, Reflexive, and voluntary blinks that 
respond differently in different contexts and the neural processes affecting them individually are 
poorly understood. There is evidence of a “central blink generator” that is at the core of the 
different types of blinks, but its existence has not been conclusively established. Without a better 
mechanistic understanding of the central blink generator and the neural activity that differentiates 
the different blink classes, any specific hypothesis linking blink rate measures to DA mediation 
of behavioral effects should be scrutinized. As mentioned previously, a thorough mechanistic 
understand is not necessary to identify useful biomarkers. What is required, however, is 
reproducibility and consistency of the correlation between the prospective biomarker and the 
disease phenotype in question. Within diseases associated with DA dysfunction BR has been 
demonstrated to be a reliable monitoring biomarker, but, its utility as a diagnostic biomarker to 
suggest DA dysregulation in atypical populations relative to health controls is questionable 
without consistent SBR and erBR dynamics for the healthy population. 
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Appendix A: Sample Characteristics and Descriptive Statistics 
 
 
 
Table 1 Overall Sample Characteristics 
FXS n = 68 (31 Female) Controls n = 54 (26 Female) 
 Mean Std. Dev. Range Mean Std. 
Dev. 
Range t Statistic (df) 
Age 21.7 10.8 6.5 – 54 26.5 14.9 6 – 54 t(120)=-1.407, 
p<.162 
Full Scale 
IQ 
59.8 19.5 47 – 121 103 10.5 76 – 124 t(115)=-14.41, 
p<.000 
Verbal Z 
Score 
-2.9 1.9 -6.7 – 1 0.1 0.7 -1.6 – 
1.1 
t(113)=-11.15, 
p<.000 
Non-Verbal 
Z Score 
-4.2 2.4 -8.6 – 
1.1 
0.2 0.7 80 – 121 t(113)=-12.99, 
p<.000 
Deviation 
IQ 
46 29.6 -10.8 – 
116 
102 8.6 80 – 121 t(113)=-13.38, 
p<.000 
SCQ 14.2 8 1 – 30 2.1 2.2 0 – 8 t(101)=9.95, 
p<.000 
Table 1a. EEG Data Sample Characteristics (Habituation task) 
FXS n=30 (12 females) Controls n=37 (16 females) 
 Mean Std. Dev. Range Mean Std. Dev. Range t Statistic (df) 
Age 25.7 10.5 13 - 53 26.8 11.9 12 - 45  t(65)=0.4, p=.69 
Full scale IQ 62.4 21.6 47 - 
115 
103.1 9.9 85 - 124 t(62)=10.1, p<.001 
Verbal Z -2.8 1.8 -6.5 –  
-0.3 
0.1 0.6 -1.4 – 
1.5 
t(60)=8.9, p<.001 
Nonverbal Z -4.6 2.6 -8.6 –  
-0.4 
0.2 0.8 -1.1 – 
1.8 
t(60)=10.3, p<.001 
Deviation IQ 43.7 30.2 -10.8 – 
94.1 
102.1 8.1 88.9 -
120.8 
t(60)=11.1, p<.001 
SCQ 13.8 8.1 1 - 29 2.3 2.4 0 - 8 t(54)=7.7, p<.001 
Table 1b. EEG Data Sample Characteristics (Chirp task) 
FXS n=36 (13 females) Controls n=39 (17 females) 
 Mean Std. Dev. Range Mean Std. Dev. Range t Statistic (df) 
Age 25.4 10.2 10-53 27.9 12.2 12-57 t(73)=0.9, p=.33 
Full scale 
IQ 
60.7 20.4 47-115 104.2 10.2 85-124 t(71)=11.8, p<.001 
Verbal Z -3.0 1.9 -6.5 - 
0.2 
0.2 0.7 -1.4 – 
2.0 
t(69)=9.6, p<.001 
Nonverbal Z -4.5 2.4 -8.6 - -
0.4 
0.2 0.7 -1.1 – 
1.8 
t(69)=11.6, p<.001 
Deviation 
IQ 
42.4 29.1 -10.8 – 
94.1 
102.9 8.3 88.9-
120.8 
t(69)=12.3, p<.001 
SCQ 14.0 7.9 1-29 2.2 2.4 0-8 t(62)=8.2, p<.001 
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Note: Only the CSP sample characteristics differed significantly relative to overall FXS sample. 
Note: Non-verbal Z score and Deviation IQ differed between CSP and overall FXS samples. 
Table 1. Descriptive Statistics 
Group EEG Task SBR (Stdv) erBR (Stdv) Blink Stdv. (Stdv) 
FXS Rest 0.32 (.21) - 0.83 (.24) 
 Chirp 0.33 (.19) 0.29 (.19) 0.86 (.29) 
 Hab 0.33 (.20) 0.33 (.19) 0.88 (.28) 
TDC Rest 0.23 (.15) - 0.76 (.21) 
 Chirp 0.25 (.18) 0.22 (.18) 0.71 (.19) 
 Hab 0.26 (.19) 0.24 (.17) 0.73 (.19) 
FXSmale Rest 0.32 (.21) - 0.84 (.26) 
 Chirp 0.30 (.17) 0.29 (.18) 0.89 (.31) 
 Hab 0.31 (.19) 0.32 (.18) 0.87 (.30) 
FXSfemale Rest 0.33 (.22) - 0.81 (.21) 
 Chirp 0.35 (.20) 0.29 (.20) 0.82 (.26) 
 Hab 0.35 (.21)  0.34 (.19) 0.89 (.28) 
TDCmale Rest 0.23 (.16) - 0.74 (.21) 
 Chirp 0.24 (.20) 0.21 (.18) 0.69 (.19) 
 Hab 0.26 (.20) 0.26 (.18) 0.73 (.21) 
TDCfemale Rest 0.24 (.14) - 0.77 (.20) 
 Chirp 0.26 (.19) 0.24 (.17) 0.72 (.18) 
 Hab 0.26 (.18) 0.22 (.16) 0.73 (.21) 
Note: Values represent link rate means (Blinks/sec) and average blink variability (stdv). 
Table 2 Data Availability (Clinical Measures) 
 FXS n = 68 (31 Female) Controls n = 54 (26 Female) 
Task Mean Age % of sample Mean Age % of sample 
KiTAP 22.4 86.7% 26.5 100% 
ADAMS 20.1 88.2% 22.1 85.6% 
ABC FXS 19.7 85.3% 21.2 77.2% 
WJ-III 20.8 80.1% - - 
VINELAND 20.9 82.4% - - 
CSP 22.9 41.2% - - 
Table 2a. Clinical Measure Sample Characteristics (CSP) 
FXS sample with CSP data n = 28 (8 Female) Overall FXS Sample n = 68 (31 Female) 
 Mean Std. Dev. Range Mean Std. Dev. Range t Stat (df) 
Age 22.9 9.9 7.5 – 
40.8 
21.7 10.8 6.5 – 54 t(66)=0.757, 
p=.452 
Full scale IQ 55.2 16.3 47 - 
115 
59.8 19.5 47 – 121 t(61)=-1.64, 
p=.105 
Verbal Z -3.4 1.8 -6.5 -  
-0.25 
-2.9 1.9 -6.7 – 1 t(59)=-1.65, 
p=.104 
Nonverbal Z -4.9 2.2 -0.7 -  
-8.6 
-4.2 2.4 -8.6 – 
1.1 
t(59)=-2.16, 
p=.035* 
Deviation 
IQ 
36.5 26.2 -10.8 
– 91.4 
46 29.6 -10.8 – 
116 
t(59)=-2.27 
p=.027* 
SCQ 14.3 6.4 4 - 26 14.2 8 1 – 30 t(56)=.081, 
p=.934 
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Figure 1: Overall FXS sample SBR distribution. 
 
 
Figure 1a: Overall TDC sample SBR distribution does not appear to be bi-modal.  
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Appendix B: Exploratory Correlations 
 
Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the FXS sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the FXS sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
Table 4 Clinical Correlations with FXS Blink Rate Measures 
EEG 
Task 
CSP 
Registration 
CSP 
Avoiding 
CSP 
Sensitivity 
ADAMS 
Manic/Hyperactive 
Behavior 
ADAMS 
Depressed 
Mood 
Full-
scale 
IQ 
Deviation 
IQ 
Verbal 
Z-score 
Rest         
SBR -.652** -.482** -.423* - -.304* - - - 
Std. Dev. -.452* - - - -.375** - - - 
Chirp         
SBR - -.538** - - - - - - 
erBR -.475* -.561** - - -.284* - - - 
Std. Dev. - - - - -.282* - - - 
Hab         
SBR -.557* -.526* -.536* -.314* -.282* - - - 
erBR -.584* -.540* -.585* - - - - - 
Std. Dev. -.480* -.525* -.472* -.401* -.324* - - - 
Table 4a Clinical Correlations with FXS Male Blink Rate Measures 
EEG 
Task 
CSP 
Registration 
CSP 
Avoiding 
CSP 
Sensitivity 
ADAMS 
Manic / 
Hyperactive 
Behavior 
ADAMS 
Depressed 
Mood 
Full-scale 
IQ 
Deviation 
IQ 
Verbal 
Z-score 
Rest         
SBR -.740** .536* -.560* - - - - - 
Std. Dev. -.494* - - - - - - - 
Chirp         
SBR - - - - - -.498** -.508** -.548** 
erBR -.526* -.516* - - - -.455* - -.419* 
Std. Dev. - - - - - -.493** -.529** -.591** 
Hab         
SBR -.518* - -.543* - - - - - 
erBR -.604* - -.604* - - -.409* - - 
Std. Dev. - - - -.390* -  - -.401* 
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Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the FXS sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4b Clinical Correlations with FXS Female Blink Rate Measures 
EEG 
Task 
CSP 
Registration 
CSP 
Avoiding 
CSP 
Sensitivity 
ADAMS 
Manic / 
Hyperactive 
ADAMS 
Depressed 
Mood 
Full-scale 
IQ 
Deviation 
IQ 
Verbal 
Z-score 
Rest         
SBR - - - - - - - - 
Std. Dev. - - - - -.542** - - - 
Chirp         
SBR - -.841* - - - - - - 
erBR - -.841* - - - - - - 
Std. Dev. - - - - -.472* - - - 
Hab         
SBR - -.928** - - - - - - 
erBR - -.928** - - - - - - 
Std. Dev. - - - - - - - - 
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Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the FXS sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
 
Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the FXS sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
 
 
Table 5 Vineland Correlations with FXS Blink Rate Measures 
EEG 
Task 
Vineland age 
equivalence 
(expressive) 
Vineland age 
equivalence 
(community) 
Vineland age 
equivalence 
(receptive) 
Vineland age 
equivalence 
(coping) 
Vineland 
Composite 
Vineland 
Comm. 
Vineland 
Social  
Vineland 
DLS 
Rest         
SBR - - - - - - - - 
Std. Dev. - - - - - - - - 
Chirp         
SBR - - - - - - - - 
erBR -.347* -.291* - - - - - -.330* 
Std. Dev. -.300* - - - -.304* - - -.355* 
Hab         
SBR - - - - - - - - 
erBR - - - .316* - - - - 
Std. Dev. - - - - - - - - 
Table 5a Vineland Correlations with FXS Male Blink Rate Measures 
EEG 
Task 
Vineland age 
equivalence 
(expressive) 
Vineland age 
equivalence 
(community) 
Vineland age 
equivalence 
(receptive) 
Vineland age 
equivalence 
(coping) 
Vineland 
Composite 
Vineland 
Comm. 
Vineland 
Social  
Vineland 
DLS 
Rest         
SBR - -.442* - - -.515**  -.397* - 
Std. Dev. - -.383* - - - -.457* -.370* - 
Chirp         
SBR - - - - -.407* -.407* - -.415* 
erBR - - - - - - - -.399** 
Std. Dev. - - - - -.505** -.505** - -.473* 
Hab         
SBR - - - - -.457* -.403* - - 
erBR - - - .502** -.501** -.531** - - 
Std. Dev. - - - - -.504** -.441* - - 
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Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the FXS sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
 
 
Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the FXS sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
Table 5b Vineland Correlations with FXS Female Blink Rate Measures 
EEG 
Task 
Vineland age 
equivalence 
(expressive) 
Vineland age 
equivalence 
(community) 
Vineland age 
equivalence 
(receptive) 
Vineland age 
equivalence 
(coping) 
Vineland 
Composite 
Vineland 
Comm. 
Vineland 
Social 
Vineland 
DLS 
Rest         
SBR - - - - - - - - 
Std. Dev. - - - - - - - - 
Chirp         
SBR - - - - - - - - 
erBR - - - - - - - - 
Std. Dev. - - - - - - - - 
Hab         
SBR - - .527* - - - - - 
erBR - - .525* - - - - - 
Std. Dev. - - .510* - - - - - 
Table 6 ABC-FXS Correlations with FXS Blink Rate Measures 
EEG 
Task 
ABC FXS 
Irritability/ 
Aggression 
ABC FXS 
Lethargy/Social 
Withdrawal 
ABC FXS 
Hyperactivity/ 
Non-Compliance 
ABC FXS 
Inappropriate 
Speech 
ABC FXS 
Social 
Avoidance 
Rest      
SBR - -.260* - - - 
Std. Dev. - -.357** - - -.264* 
Chirp      
SBR - - - - - 
erBR - - - - - 
Std. Dev. - - - - - 
Hab      
SBR - -.309* - - - 
erBR - - - - - 
Std. Dev. -.367* -.402** -.344* -.357* - 
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Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the FXS sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
 
Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the FXS sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
Table 6a ABC-FXS Correlations with FXS Male Blink Rate Measures 
EEG 
Task 
ABC FXS 
Irritability/ 
Aggression 
ABC FXS 
Lethargy/Social 
Withdrawal 
ABC FXS 
Hyperactivity/ 
Non-Compliance 
ABC FXS 
Inappropriate 
Speech 
ABC FXS 
Social 
Avoidance 
Rest      
SBR - - - - - 
Std. Dev. - - - - - 
Chirp      
SBR - - - - - 
erBR - - - - - 
Std. Dev. - - - - - 
Hab      
SBR - - - - - 
erBR - - - - - 
Std. Dev. - - - -.429* - 
Table 6b ABC-FXS Correlations with FXS Female Blink Rate Measures 
EEG 
Task 
ABC FXS 
Irritability/ 
Aggression 
ABC FXS 
Lethargy/Social 
Withdrawal 
ABC FXS 
Hyperactivity/ 
Non-Compliance 
ABC FXS 
Inappropriate 
Speech 
ABC FXS 
Social 
Avoidance 
Rest      
SBR - - - - - 
Std. Dev. - -.501* - - - 
Chirp      
SBR - - - - - 
erBR - - - - - 
Std. Dev. - - - - - 
Hab      
SBR - - - - - 
erBR - - - - - 
Std. Dev. - - - - -.454* 
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Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the FXS sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
 
Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the FXS sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
 
 
Table 7 kiTAP Correlations with FXS Blink Rate Measures 
EEG 
Task 
Distractor 
Correct 
Distractor 
Omissions 
Distractor 
Median 
Distractor 
Errors 
Total Distractor 
Errors 
No-Distractor 
Errors 
Flex 
Correct 
gonogo 
Errors 
Rest         
SBR .270* -.261* - - - - - - 
Std. Dev. - - - - - - - - 
Chirp         
SBR - - - - - - - - 
erBR - - - - - - - - 
Std. Dev. - - - - - - - - 
Hab         
SBR - - - - - - - - 
erBR - - - - - - - - 
Std. Dev. - - - - - - - - 
Table 7a kiTAP Correlations with FXS Male Blink Rate Measures 
EEG 
Task 
Distractor 
Correct 
Distractor 
Omissions 
Distractor 
Median 
Distractor 
Errors 
Distractor Total 
Errors 
No-Distractor 
Errors 
Flex 
Correct 
gonogo 
Errors 
Rest         
SBR - - - .501** .450* .391* - - 
Std. Dev. - - - - - - - - 
Chirp         
SBR - - - .404* - - - .413* 
erBR - - -.405* - - - - - 
Std. Dev. - - - - - - - - 
Hab         
SBR - - - .462* .460* .445* - .583** 
erBR - - - .543** .507** .443* - .596** 
Std. Dev. - - - - - - - - 
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Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the FXS sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
 
Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the FXS sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
Table 7b kiTAP Correlations with FXS Female Blink Rate Measures 
EEG 
Task 
Distractor 
Correct 
Distractor 
Omissions 
Distractor 
Median 
Distractor 
Errors 
Total Distractor 
Errors 
No-Distractor 
Errors 
Flex 
Correct 
gonogo 
Errors 
Rest         
SBR - - - - - - .501* - 
Std. Dev. - - - - - - - - 
Chirp         
SBR - - - - - - - - 
erBR - - - - - - - - 
Std. Dev. - - - - - - - - 
Hab         
SBR - - - - - - - - 
erBR - - - - - - - - 
Std. Dev. - - - - - - - - 
Table 8 FXS Blink Rate Correlations with EEG Measures 
EEG 
Task 
ERP 
Onset ITC 
(Chirp) 
ERP 
Offset ITC 
(Chirp) 
Theta 
Power 
(Chirp) 
ERP 
Onset ITC 
(Hab) 
ERP 
Offset ITC 
(Hab) 
Alpha 
Power 
(Hab) 
Theta 
Power 
(Hab) 
P2_3 
Latency 
(Hab) 
%habituation 
N1  
amplitude 
Rest          
SBR - - - - - - - - .394* 
Std. Dev. - - - - - - - - - 
Chirp          
SBR - - - - - - - - - 
erBR - - - - - - - - - 
Std. Dev. - - - - - - - - - 
Hab          
SBR - - - - - - - -.463* - 
erBR - - - - - - - -.402* - 
Std. Dev. - - - - - - - - .430* 
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Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the FXS sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
 Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the FXS sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
 
 
Table 8a FXS Male Blink Rate Correlations with EEG Measures 
EEG 
Task 
ERP 
Onset ITC 
(Chirp) 
ERP 
Offset ITC 
(Chirp) 
Theta 
Power 
(Chirp) 
ERP 
Onset ITC 
(Hab) 
ERP 
Offset ITC 
(Hab) 
Alpha 
Power 
(Hab) 
Theta 
Power 
(Hab) 
P2_3 
Latency 
(Hab) 
%habituation 
N1  
amplitude 
Rest          
SBR - - - - - - .564* - - 
Std. Dev. - - - - - - .564* - - 
Chirp          
SBR - - - - - - - - - 
erBR - - - - - - - - - 
Std. Dev. - - - - - - - - - 
Hab          
SBR - - - - - - - -.514* - 
erBR - - - - - - - - - 
Std. Dev. - - - -.494* - .618** .707** - .524* 
Table 8b FXS Female Blink Rate Correlations with EEG Measures 
EEG 
Task 
ERP 
Onset ITC 
(Chirp) 
ERP 
Offset ITC 
(Chirp) 
Theta 
Power 
(Chirp) 
ERP 
Onset ITC 
(Hab) 
ERP 
Offset ITC 
(Hab) 
Alpha 
Power 
(Hab) 
Theta 
Power 
(Hab) 
P2_3 
Latency 
(Hab) 
%habituation 
N1  
amplitude 
Rest          
SBR - .720** - .845** - - -.727* - - 
Std. Dev. - .727** - .682* - - - - - 
Chirp          
SBR - .709** - - - - - - - 
erBR - .602* - - - - - - - 
Std. Dev. - .703** - - - - - - - 
Hab          
SBR - - - .671* - - - - - 
erBR - - - .685* - - -.643* - - 
Std. Dev. - - - - - - - - - 
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Clinical variables with significant correlations to blink measures are included. All correlations 
are Spearman’s Rho and represent the TDC sample only. Correlations that did not survive 
correction for multiple comparisons are highlighted in red. “-“ = N.S., *p < 0.05, **p < 0.01. 
 
 
 
 
 
 
 
 
 
 
Table 8c TDC Blink Rate Correlations for EEG Measures 
EEG 
Task 
Alpha 
Power 
(Hab) 
Theta 
Power 
(Hab) 
N1_2 
Latency 
(Hab) 
N1_3 
Latency 
(Hab) 
Rep1 
ITC 
(Hab) 
Rep2 
ITC 
(Hab) 
Rep3 
ITC 
(Hab) 
P2_2 
Amplitude 
(Hab) 
ERP Onset 
ITC 
(Hab) 
Rest          
SBR - - - -.380* - - -.424* - - 
Std. Dev. .338* - - -.425* -.448** -.578** -.511** - -.329* 
Chirp          
SBR - - -.424* - - - -.355* - - 
erBR - - -.459** - - -.366* -.417* - - 
Std. Dev. - - -.400* - - -.340* - - - 
Hab          
SBR .519** - -.411* -.417* -.429* -.481** -.481** -.372* - 
erBR .605** .374* -.491** -.443** -.378* -.404* -.464** - - 
Std. Dev. .437** - -.420* -.362* -.471** -.497** -.475** - -.376* 
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Appendix C: Blink Rate Measures Across Tasks 
 
 
Figure 2. Resting SBR is significantly elevated in the FXS sample relative to TDCs (p = 0.013). 
 
 
Figure 2a.Resting SBR is not significantly different between genders in either group (p = 0.848). 
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Figure 3. OBR (p = 0.023), and SBR (p = 0.042) are significantly elevated in the FXS relative to 
TDCs. A marginally significant elevation of erBR in the FXS sample was observed (p = 0.053). 
 
 
Figure 3a. No significant between-subject effects of sex (p = 0.530) or the group*sex interaction 
(p = 0.987). A significant within-subject effect of the group*sex*stim interaction was found (p = 
0.021) due to a lack of modulation of BR between erBR and SBR in FXS males only. 
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Figure 4.: Significantly elevated OBR (p = 0.023) and erBR (p = 0.012) in the FXS group along 
with a marginally significant increase in SBR (p = 0.058). 
 
 
Figure 4a.  No significant, between-subject effects of sex (p = 0.823) or the group*sex 
interaction (p = 0.470). A within-subject effect of the sex*stim interaction approached significant 
(p = 0.061) with males modulating BR in response to stimuli to a less extent than females. No 
significant effect of the group*sex*stim interaction was found (p = 0.768). 
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Appendix D: Blink Identification 
 
 
 
 
 
 
 
 
 
 
Figure 5. Example of 3d spatial distribution of scalp potentials alongside EEG channel 
waveforms characteristic of blinks.  Virtual Electro-oculogram waveforms are shown below 
channel data (blue waveforms) and are produced in BESA by applying predefined source model 
to the data. This creates three topographies accounting for EOG activity (Horizontal, vertical, 
and blink topographies). vEOG waveforms help disambiguate blinks from other forms of eye-
movement related signal. 
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Appendix E: EEG Channel Montage and Previous Results 
 
 
Figure 6. Sensory layout of the EGI 128 channel system used for data collection. Sensors 
selected for further EEG analyses are highlighted in red. Sensor selection was based on standards 
used in previous aimed at detecting N1 ERP components originating in the auditory cortex. 
Reproduced with permission (Ethridge et al., 2019). Copyright (2019), [Front. Integr. 
Neurosci.]. 
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Figure 6a. Average ERP waveforms for FXS (red) and TDC (black) samples for the habituation 
task. Black bars on the horizontal axis represent stimulus presentation of each burst of the train. 
Significantly increased N1 and P2 amplitude in FXS as compared to controls. Reproduced with 
permission (Ethridge et al., 2019). Copyright (2019), [Front. Integr. Neurosci.]. 
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Figure 6b. a) Single trial power (STP) and difference map (FXS – TDC) for the chirp task. b) 
ITC for TDC and FXS samples along with difference map. Clusters with significant group 
differences in the difference maps are indicated by black boxes. Reproduced with permission 
(Ethridge et al., 2019). Copyright (2019), [Front. Integr. Neurosci.]. 
